Price T Rowe Associates Inc. MD Buys 3,842 Shares of Maximus, Inc. (NYSE:MMS)

Price T Rowe Associates Inc. MD increased its position in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 9.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,478 shares of the health services provider's stock after buying an additional 3,842 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.08% of Maximus worth $3,321,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. UMB Bank n.a. grew its stake in Maximus by 79.8% during the 4th quarter. UMB Bank n.a. now owns 356 shares of the health services provider's stock worth $27,000 after purchasing an additional 158 shares in the last quarter. Eastern Bank purchased a new stake in shares of Maximus in the 4th quarter valued at approximately $29,000. V Square Quantitative Management LLC raised its holdings in shares of Maximus by 65.9% in the 4th quarter. V Square Quantitative Management LLC now owns 453 shares of the health services provider's stock valued at $34,000 after purchasing an additional 180 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Maximus during the 4th quarter worth $54,000. Finally, IFP Advisors Inc grew its stake in shares of Maximus by 62.4% during the fourth quarter. IFP Advisors Inc now owns 786 shares of the health services provider's stock worth $59,000 after purchasing an additional 302 shares in the last quarter. Institutional investors and hedge funds own 97.21% of the company's stock.

Maximus Trading Down 0.6 %

NYSE MMS traded down $0.43 during trading hours on Friday, hitting $75.31. 598,966 shares of the company's stock were exchanged, compared to its average volume of 562,674. Maximus, Inc. has a 12-month low of $63.77 and a 12-month high of $93.97. The business's 50 day moving average is $68.07 and its 200-day moving average is $73.15. The firm has a market capitalization of $4.26 billion, a P/E ratio of 16.20 and a beta of 0.61. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.72 and a current ratio of 1.72.

Maximus (NYSE:MMS - Get Free Report) last posted its earnings results on Thursday, May 8th. The health services provider reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.64. Maximus had a net margin of 5.28% and a return on equity of 21.95%. The business had revenue of $1.36 billion for the quarter, compared to analysts' expectations of $1.29 billion. During the same period in the previous year, the company posted $1.57 earnings per share. The business's revenue for the quarter was up 1.0% compared to the same quarter last year. As a group, analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Saturday, May 31st. Shareholders of record on Thursday, May 15th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.59%. Maximus's dividend payout ratio (DPR) is 25.81%.

Insider Transactions at Maximus

In other news, Director Jan Madsen sold 2,439 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $67.71, for a total transaction of $165,144.69. Following the transaction, the director now owns 18,097 shares in the company, valued at $1,225,347.87. This represents a 11.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ilene R. Baylinson sold 14,500 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $68.14, for a total value of $988,030.00. Following the completion of the sale, the insider now owns 2,512 shares of the company's stock, valued at approximately $171,167.68. This trade represents a 85.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com raised Maximus from a "hold" rating to a "buy" rating in a research report on Wednesday.

Maximus Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.